Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the EU / 2025-522525-34-00
Authorised, recruiting Phase IV

Effect of Semaglutide on embryo quality in overweight and obese patients undergoing In Vitro Fertilization. A Randomized Controlled Trial

2025-522525-34-00 · tracked via the Priya Life Science EU tracker
Sponsor
Santiago Dexeus Font Fundacio Privada
Sponsor type
Laboratory/Research/Testing facility
Therapeutic area
Female Urogenital Diseases and Pregnancy Complications
Decision date
24/10/2025
Enrollment target
62
Sites
Spain

Condition studied

Infertility

Investigational medicinal product(s)

Wegovy 1 mg solution for injection in pre-filled penGanirelix Gedeon Richter 0.25 mg/0.5 mL solution for injection in pre-filled syringeBemfola 300 IU/0.50 mL solution for injection in pre-filled penDecapeptyl diario 0,1 mg polvo y disolvente para solución inyectable

Eligibility

Age group
18-64 years
Sex
Female

Primary endpoint

Number of good quality blastocysts

Endpoint detail

Days of stimulation, Total dose of Gonadotropins, Number Cumulus-oocyte complex (COCs), Number MII, Fertilization rate, Time of appearance of the 2nd polar body (tPB2), Time of pronuclei appearance (tPNa), Evaluation of both pronuclei (PN), Time of pronuclei disappearance (tPNf), Time of division from 2 to 8 cells (t2, t3, t4, t5, t6, t7, t8), Time of compaction (tSC), Time of morula (tM), Time of cavitation (tSB), Time of full blastulation (tB), Total number of day 5 blastocysts, Blastocyst formation rate, defined as the proportion of 2PN zygotes that reach the blastocyst stage, Number of embryos cryopreserved, Embryo stage (D5, D6, D7), Ovarian reserve markers (Antral Follicle Count,(AFC), Antimullerian Hormone (AMH)) before and after the treatment with semaglutide, Change in body weight and BMI, before and after the treatment with semaglutide, Change in WC, before and after the treatment with semaglutide

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522525-34-00 on CTIS ↗ ← All trials in the EU